E2F1-induced ferritin heavy chain 1 pseudogene 3 (FTH1P3) accelerates non-small cell lung cancer gefitinib resistance.
Antineoplastic Agents
/ pharmacology
Carcinoma, Non-Small-Cell Lung
/ diagnosis
Cell Line, Tumor
Drug Resistance, Neoplasm
Female
Gefitinib
/ pharmacology
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Lung Neoplasms
/ diagnosis
Male
Middle Aged
Prognosis
RNA, Long Noncoding
/ genetics
Up-Regulation
/ drug effects
FTH1P3
LSD1
Non-small cell lung cancer
TIMP3
lncRNA
Journal
Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
received:
18
06
2020
accepted:
09
07
2020
pubmed:
9
8
2020
medline:
17
3
2021
entrez:
9
8
2020
Statut:
ppublish
Résumé
Long noncoding RNAs (lncRNAs) have been identified to be critical regulator for various human diseases and emerging evidence illustrate the essential function of lncRNAs in the non-small cell lung cancer (NSCLC). Here, our research team tried to identify the roles of lncRNA ferritin heavy chain 1 pseudogene 3 (FTH1P3) in the NSCLC, as well as its molecular mechanism. LncRNA microarray analysis revealed that ferritin heavy chain 1 pseudogene 3 (FTH1P3) was up-regulated in the gefitinib-resistant cells (PC9/GR). Clinically, lncRNA FTH1P3 high-expression was closely correlated with NSCLC patients' unfavorable prognosis. Gain and loss of functional experiments revealed that FTH1P3 promoted the proliferation and invasion of NSCLC cells in vitro, and FTH1P3 knockdown repressed the tumor growth in vivo. Mechanistically, transcription factor E2F1 accelerated the transcription of FTH1P3. RNA immunoprecipitation and chromatin immunoprecipitation experiments showed that FTH1P3 can recruit lysine-specific demethylase 1 (LSD1) and epigenetically repress the TIMP3, thereby accelerating the tumorigenesis of NSCLC. In summary, these findings suggest that FTH1P3 plays a critical role in the gefitinib resistance and progression of NSCLC, providing a potential novel prognostic marker for NSCLC.
Identifiants
pubmed: 32762943
pii: S0006-291X(20)31431-5
doi: 10.1016/j.bbrc.2020.07.044
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
RNA, Long Noncoding
0
long non coding RNA FTH1P3, human
0
Gefitinib
S65743JHBS
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
624-631Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest All authors declare no conflicts of interest.